Joseph Monahan Aclaris Therapeutics, Inc. (ACRS) insider trading activity

Joseph Monahan is Chief Scientific Officer of Aclaris Therapeutics, Inc.. Currently has a direct ownership of 231,995 shares of ACRS, which is worth approximately $487,189. The most recent transaction as insider was on Feb 01, 2025, when has been sold 11,317 shares (Common Stock) at a price of $2.48 per share, resulting in proceeds of $28,066. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 232K

24.21% 3M change

72.31% 12M change

Total Value Held $487,189

Joseph Monahan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 01 2025	SELL Payment of exercise price or tax liability	$28,066 $2.48 p/Share	11,317 Reduced 4.65%	231,995 Common Stock
Feb 01 2025	BUY Exercise of conversion of derivative security	-	22,250 Added 8.38%	243,312 Common Stock
Jan 02 2025	SELL Payment of exercise price or tax liability	-	8,914 Reduced 3.88%	221,062 Common Stock
Jan 02 2025	BUY Exercise of conversion of derivative security	-	17,380 Added 7.03%	229,976 Common Stock
Dec 31 2024	SELL Payment of exercise price or tax liability	-	32,937 Reduced 13.41%	212,596 Common Stock
Dec 31 2024	BUY Exercise of conversion of derivative security	-	73,750 Added 23.1%	245,533 Common Stock
Dec 10 2024	SELL Bona fide gift	-	15,000 Reduced 8.03%	171,783 Common Stock
Mar 02 2024	SELL Payment of exercise price or tax liability	$4,378 $1.24 p/Share	3,531 Reduced 1.86%	186,783 Common Stock
Mar 02 2024	BUY Exercise of conversion of derivative security	-	12,500 Added 6.16%	190,314 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$22,012 $1.24 p/Share	17,752 Reduced 9.08%	177,814 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	-	60,925 Added 25.18%	180,997 Common Stock
Feb 01 2024	SELL Payment of exercise price or tax liability	$3,099 $1.2 p/Share	2,583 Reduced 1.88%	134,641 Common Stock
Feb 01 2024	BUY Exercise of conversion of derivative security	-	7,500 Added 5.18%	137,224 Common Stock
Oct 23 2023	SELL Open market or private sale	$30,480 $5.08 p/Share	6,000 Reduced 4.42%	129,724 Common Stock
Aug 21 2023	SELL Open market or private sale	$43,920 $7.32 p/Share	6,000 Reduced 4.23%	135,724 Common Stock
Jun 20 2023	SELL Open market or private sale	$61,679 $10.28 p/Share	6,000 Reduced 4.06%	141,724 Common Stock
Mar 03 2023	SELL Open market or private sale	$202,547 $12.63 p/Share	16,037 Reduced 9.79%	147,724 Common Stock
Mar 02 2023	SELL Open market or private sale	$183,076 $12.37 p/Share	14,800 Reduced 8.91%	151,261 Common Stock
Mar 02 2023	BUY Exercise of conversion of derivative security	-	12,500 Added 7.09%	163,761 Common Stock
Mar 01 2023	BUY Exercise of conversion of derivative security	-	74,675 Added 31.02%	166,061 Common Stock
Feb 15 2023	SELL Open market or private sale	$65,300 $13.06 p/Share	5,000 Reduced 5.19%	91,386 Common Stock
Dec 15 2022	SELL Open market or private sale	$79,400 $15.88 p/Share	5,000 Reduced 4.93%	96,386 Common Stock
Oct 17 2022	SELL Open market or private sale	$79,900 $15.98 p/Share	5,000 Reduced 4.7%	101,386 Common Stock
Apr 18 2022	SELL Open market or private sale	$488,400 $16.28 p/Share	30,000 Reduced 22.0%	106,386 Common Stock
Mar 10 2022	SELL Open market or private sale	$426,762 $15.71 p/Share	27,165 Reduced 16.61%	136,386 Common Stock

Joseph Monahan

Chief Scientific Officer

Wayne, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRS shares.

Notify only if

Value

Insider Trading

Get notified when an Aclaris Therapeutics, Inc. insider buys or sells ACRS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aclaris Therapeutics, Inc.

Track Activities on ACRS

Account